Lv1
50 积分 2025-12-16 加入
Efficacy and Safety of Bepirovirsen in Hepatitis B
1个月前
已完结
WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
1个月前
已关闭
Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon
1个月前
已完结
[Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)]
1个月前
已完结
Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries
2个月前
已完结
Correlates of chronic hepatitis B virus infection in the general adult population of China: Systematic review and meta‐analysis
2个月前
已完结
Efficacy and Safety of Bepirovirsen in Hepatitis B
2个月前
已完结
Heterogeneity of HBV-Specific CD8+ T-Cell Failure: Implications for Immunotherapy
2个月前
已完结
Molecular biology of hepatitis B virus infection
6个月前
已完结
Hepatitis B virus persistence in mice reveals IL-21 and IL-33 as regulators of viral clearance
7个月前
已完结
皖公网安备34019202002308
